Skip to main content

Table 9 Age-Adjusted Charlson Comorbidity Index (ACCI) [22]

From: Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

Age

< 50

0

50–59

+ 1

60–69

+ 2

70–79

+ 3

≥ 80

+ 4

Myocardial infarction

No 0

Yes + 1

Chronic heart failure

No 0

Yes + 1

Peripheral vascular disease

No 0

Yes + 1

Cerebral vascular accident or transient ischemic attack

No 0

Yes + 1

Hemiplegia

No 0

Yes + 2

Dementia = (chronic cognitive impairment)

No 0

Yes + 1

Chronic obstructive pulmonary disease

No 0

Yes + 1

Connective tissue disease

No 0

Yes + 1

Peptic ulcer disease

No 0

Yes + 1

Liver disease

None

0

Mild

+ 1

Moderate to severe

+ 3

Diabetes mellitus

None or diet controlled 0

Uncomplicated

+ 1

End-organ damage

+ 2

Moderate to severe chronic kidney disease

No 0

Yes + 1

Solid tumour

None

0

Localised

+ 2

Metastatic

+ 6

Leukaemia

No 0

Yes + 2

Lymphoma

No 0

Yes + 2

AIDS

No 0

Yes + 2